These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
686 related articles for article (PubMed ID: 12114403)
21. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
22. Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes. Voogt PJ; Falkenburg JH; Fibbe WE; Veenhof WF; Hamilton M; Van Krimpen BA; Bolhuis RL J Immunol; 1989 Mar; 142(5):1774-80. PubMed ID: 2521886 [TBL] [Abstract][Full Text] [Related]
23. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering. Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014 [TBL] [Abstract][Full Text] [Related]
24. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease. Xia G; Kovochich M; Truitt RL; Johnson BD Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606 [TBL] [Abstract][Full Text] [Related]
25. Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells. Overes IM; Fredrix H; Kester MG; Falkenburg JH; van der Voort R; de Witte TM; Dolstra H J Immunother; 2009; 32(6):539-51. PubMed ID: 19483655 [TBL] [Abstract][Full Text] [Related]
26. Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versus-leukemia response. Takami A; Sugimori C; Feng X; Yachie A; Kondo Y; Nishimura R; Kuzushima K; Kotani T; Asakura H; Shiobara S; Nakao S Bone Marrow Transplant; 2004 Oct; 34(8):703-9. PubMed ID: 15322566 [TBL] [Abstract][Full Text] [Related]
28. CTL clones isolated from an HLA-Cw-mismatched bone marrow transplant recipient with acute graft-versus-host disease. Sugimoto K; Murata M; Terakura S; Naoe T J Immunol; 2009 Nov; 183(9):5991-8. PubMed ID: 19812210 [TBL] [Abstract][Full Text] [Related]
29. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791 [TBL] [Abstract][Full Text] [Related]
30. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307 [TBL] [Abstract][Full Text] [Related]
31. Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs. Fujiwara H; Sconocchia G; Melenhorst J; Eniafe R; Nakamura R; Hensel N; Barrett AJ Bone Marrow Transplant; 2003 Aug; 32(4):371-8. PubMed ID: 12900773 [TBL] [Abstract][Full Text] [Related]
32. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Kaminski E; Hows J; Man S; Brookes P; Mackinnon S; Hughes T; Avakian O; Goldman JM; Batchelor JR Transplantation; 1989 Oct; 48(4):608-13. PubMed ID: 2508280 [TBL] [Abstract][Full Text] [Related]
33. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011 [TBL] [Abstract][Full Text] [Related]
34. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882 [TBL] [Abstract][Full Text] [Related]
35. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice. Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837 [TBL] [Abstract][Full Text] [Related]
36. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model. Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433 [TBL] [Abstract][Full Text] [Related]
37. A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes. Yazaki M; Takahashi T; Andho M; Akatsuka Y; Ito T; Miyake Y; Ito Y; Nakamura S; Wada Y Bone Marrow Transplant; 1999 Jul; 24(2):129-37. PubMed ID: 10455340 [TBL] [Abstract][Full Text] [Related]
38. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells. Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973 [TBL] [Abstract][Full Text] [Related]
39. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion. Levenga H; Woestenenk R; Schattenberg AV; Maas F; Jansen JH; Raymakers R; De Mulder PH; van de Wiel-van Kemenade E; Schaap N; de Witte T; Dolstra H Bone Marrow Transplant; 2007 Sep; 40(6):585-92. PubMed ID: 17637687 [TBL] [Abstract][Full Text] [Related]
40. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Li JM; Waller EK Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]